Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 10 11:57AM ET
3.87
Dollar change
+0.06
Percentage change
1.63
%
Index- P/E- EPS (ttm)-3.12 Insider Own42.69% Shs Outstand34.06M Perf Week1.63%
Market Cap131.88M Forward P/E- EPS next Y-1.10 Insider Trans0.00% Shs Float19.52M Perf Month-10.78%
Income-71.24M PEG- EPS next Q-0.44 Inst Own25.15% Short Float0.52% Perf Quarter-12.00%
Sales24.99M P/S5.28 EPS this Y-15.42% Inst Trans299.21% Short Ratio2.01 Perf Half Y35.38%
Book/sh-2.28 P/B- EPS next Y58.02% ROA-148.77% Short Interest0.10M Perf Year195.57%
Cash/sh0.53 P/C7.25 EPS next 5Y- ROE- 52W Range1.14 - 5.24 Perf YTD79.26%
Dividend Est.- P/FCF- EPS past 5Y-17.26% ROI- 52W High-26.11% Beta0.73
Dividend TTM- Quick Ratio0.68 Sales past 5Y-5.10% Gross Margin42.45% 52W Low239.65% ATR (14)0.23
Dividend Ex-Date- Current Ratio0.76 EPS Y/Y TTM-38.56% Oper. Margin-87.99% RSI (14)49.94 Volatility5.64% 6.34%
Employees54 Debt/Eq- Sales Y/Y TTM-48.37% Profit Margin-285.10% Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-72.88% Payout- Rel Volume0.05 Prev Close3.81
Sales Surprise-5.40% EPS Surprise-245.45% Sales Q/Q-38.90% EarningsAug 07 AMC Avg Volume50.15K Price3.87
SMA20-0.23% SMA502.80% SMA2009.98% Trades Volume1,128 Change1.63%
Date Action Analyst Rating Change Price Target Change
Nov-02-20Initiated Truist Buy $20
Nov-02-20Initiated Piper Sandler Overweight $20
Nov-02-20Initiated Cowen Outperform $20
Nov-02-20Initiated Cantor Fitzgerald Overweight $20
Sep-18-24 08:00AM
Sep-06-24 04:23PM
Sep-05-24 04:05PM
Sep-03-24 04:05PM
Aug-21-24 07:00AM
07:00AM Loading…
Aug-20-24 07:00AM
Aug-07-24 04:05PM
Aug-01-24 04:05PM
Jul-31-24 04:05PM
Jul-30-24 04:05PM
Jul-17-24 04:15PM
07:00AM
Jul-16-24 07:00AM
Jul-11-24 04:05PM
03:24PM
08:01AM Loading…
Jun-17-24 08:01AM
08:00AM
May-13-24 08:00AM
May-09-24 10:55PM
04:05PM
May-02-24 04:05PM
Apr-29-24 09:00AM
Apr-24-24 04:05PM
Mar-07-24 09:53PM
04:05PM
Feb-22-24 04:05PM
Feb-20-24 10:37AM
Jan-10-24 04:05PM
Dec-18-23 08:00AM
Nov-13-23 04:05PM
08:30AM Loading…
Nov-09-23 08:30AM
Nov-06-23 04:05PM
Oct-18-23 08:00AM
Sep-20-23 08:30AM
Sep-19-23 08:36AM
Sep-18-23 04:08PM
Sep-08-23 08:30AM
Sep-06-23 04:05PM
Aug-30-23 08:30AM
Aug-21-23 09:42AM
Aug-15-23 05:21AM
Aug-14-23 04:05PM
Jul-31-23 04:05PM
Jul-26-23 03:29PM
Jul-17-23 04:05PM
Jul-13-23 04:30PM
May-19-23 01:45PM
08:15AM
May-13-23 08:17AM
May-11-23 09:58AM
05:51AM
May-10-23 04:05PM
May-03-23 04:05PM
10:42AM
Apr-20-23 04:30PM
Apr-17-23 06:11AM
Apr-05-23 09:55AM
Mar-27-23 06:26AM
Mar-23-23 06:08AM
Mar-22-23 04:01PM
08:30AM
Mar-20-23 12:01PM
08:00AM
Mar-15-23 04:05PM
Feb-27-23 08:15AM
Jan-31-23 08:00AM
Jan-26-23 12:00PM
09:40AM
Jan-21-23 09:58AM
Jan-09-23 08:15AM
Dec-15-22 08:00AM
Dec-10-22 07:38AM
Dec-01-22 09:04AM
Nov-30-22 04:08PM
Nov-21-22 04:05PM
Nov-16-22 06:00AM
Nov-14-22 05:25PM
04:01PM
Nov-07-22 04:05PM
07:40AM
Oct-25-22 09:47AM
Oct-24-22 08:00AM
Oct-18-22 04:05PM
Oct-11-22 04:35PM
07:44AM
Aug-26-22 09:00AM
Aug-17-22 04:05PM
Aug-16-22 01:53PM
Aug-14-22 10:16AM
Aug-11-22 04:05PM
03:09PM
Aug-10-22 06:56PM
Aug-09-22 05:58PM
Jul-28-22 04:05PM
Jul-20-22 09:40AM
Jun-27-22 04:15AM
Jun-21-22 04:05PM
Jun-01-22 08:50AM
May-09-22 05:25PM
04:05PM
Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women's Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women's Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ferguson MatthewCHIEF FINANCIAL OFFICERJul 31 '24Option Exercise1.43105,080150,002257,823Jul 31 05:00 PM
Ferguson MatthewCHIEF FINANCIAL OFFICERMar 08 '24Option Exercise0.001,2880121,807Mar 14 04:43 PM